In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
ID: 345388Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345388

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-074.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability" (FOA Number PAR-23-074). This initiative aims to encourage research applications that focus on detailed phenotyping and hypothesis-driven studies utilizing knockout mouse strains developed by the International Mouse Phenotyping Consortium (IMPC), with the goal of investigating critical genes involved in embryonic development and associated disorders. The funding opportunity is significant for advancing understanding of congenital diseases and infertility, with a maximum budget of $499,999 per year and a project period of up to five years. Interested applicants must adhere to NIH guidelines and submit their proposals by the initial application deadline of June 5, 2023, with further inquiries directed to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-074-Full-Announcement.html
    PAR-23-074.html
    The Department of Health and Human Services, through the National Institutes of Health, has announced a funding opportunity (FOA) titled “In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability" (FOA Number PAR-23-074). This initiative encourages research applications focusing on detailed phenotyping and hypothesis-driven studies utilizing knockout (KO) mouse strains developed by the International Mouse Phenotyping Consortium. The aim is to investigate critical genes involved in embryonic development and associated disorders, facilitating a deeper understanding of congenital diseases and infertility. Key deadlines include an initial application due date of June 5, 2023, with a maximum project period of five years and budgets up to $499,999 per year. The funding targets institutions such as higher education and nonprofit organizations. The FOA emphasizes a rigorous application process, requiring adherence to NIH guidelines and encouraging exploration of both hypothesis-driven and non-hypothesis-driven research approaches. Researchers should utilize existing resources and data from the KOMP2 program, contributing to shared scientific knowledge and addressing pertinent health issues accordingly. The document details eligibility, application procedures, review criteria, and compliance expectations, aiming for a broad range of impactful scientific inquiries.
    Similar Opportunities
    In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for in-depth phenotyping and research using knockout mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Clinical Trial Not Allowed grant mechanism. This initiative aims to encourage applications that leverage the International Mouse Phenotyping Consortium (IMPC) resources to better understand genetic functions related to congenital diseases and structural defects, particularly those affecting embryonic development and fertility. The program is part of a broader effort to catalog mammalian gene function, with an award ceiling of $499,999 per year for projects lasting up to five years. Interested applicants must submit their proposals by January 7, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the development of animal models and related biological materials for research, designated as an R21 Exploratory/Developmental Research Grant. This funding initiative aims to support innovative projects that enhance, characterize, and preserve animal models relevant to human health and diseases, with a focus on studies that encompass multiple body systems or disease categories rather than single-disease research. The total funding available is $200,000, with a project period limited to two years, and applications are due by January 7, 2028. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-273.html.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at developing and validating model systems for neurotherapeutic discovery. This initiative encourages proposals for animal models or ex vivo systems that accurately replicate the characteristics of specific neurological or neuromuscular disorders, with the goal of enhancing the translational relevance of these models to improve drug development processes. The program utilizes a phased award mechanism (R61/R33) and requires collaboration with clinical experts, along with a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The total funding available is $750,000 over three years, with a maximum of $499,000 in direct costs per year. Key submission dates begin with the earliest application due date of January 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R24 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the Office of Research Infrastructure Programs (ORIP), is offering a funding opportunity (PAR-23-039) aimed at developing resources and technologies to enhance the rigor, reproducibility, and translatability of animal models in biomedical research. This initiative encourages applicants to propose broadly applicable technologies that address critical gaps in animal research, focusing on various animal models and ensuring that the proposed resources have significant impact across multiple NIH Institutes and Centers. Successful proposals should demonstrate the necessity and broad applicability of the resources, with project durations of up to four years and no budget limits, although requests exceeding $500,000 require prior approval. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for May 25, 2025.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Resource-Related Research Projects for Development of Animal Models and Related Materials," aimed at advancing research that develops and enhances animal models relevant to human diseases. The initiative seeks applications that demonstrate the need for and potential impact of broadly applicable resources across multiple NIH Institutes and Centers, emphasizing projects that address diseases affecting multiple body systems rather than those focused on specific diseases or singular NIH interests. Eligible applicants include higher education institutions, nonprofit organizations, and government agencies, with funding available up to $5 million per year. The application deadline is set for January 25, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.